| Literature DB >> 35721625 |
Kirsten L Johansen1, Anjali Acharya2, Borut Cizman3, Alexander R Cobitz3, Ricardo Correa-Rotter4, Indranil Dasgupta5,6, Vijay Kher7, Renato D Lopes8, Leonardo Matsumoto9, Amy M Meadowcroft3, Osvaldo Merege Vieira Neto10, Marilu Okabe9, Brian Rayner11, Arnold Silva12, Hilary Thomas9, Ajay K Singh13.
Abstract
The coronavirus disease 2019 pandemic has had an unprecedented effect on health and health care and posed challenges to the conduct of clinical trials.Targeted mitigating strategies, on the basis of early and continued data collection from site surveys, limited disruption to the ASCEND trials.Flexibly allowing hemoglobin assessment at local laboratories to inform randomized treatment dosing was key to limiting the discontinuation of treatment.Entities:
Keywords: COVID-19; SARS-CoV-2; chronic kidney disease; clinical trial; dialysis; pandemics
Mesh：
Year: 2022 PMID： 35721625 PMCID： PMC9136902 DOI： 10.34067/KID.0006212021
Source DB: PubMed Journal: Kidney360 ISSN： 2641-7650